BPC-157 vs TB-500: A Research Comparison
Written by Elyte Peptides Research Team
How BPC-157 and TB-500 differ — origin, molecular size, studied mechanisms, and why researchers often examine them together as the so-called 'Wolverine' combination.
TL;DR: BPC-157 is a synthetic, stabilized pentadecapeptide (15 amino acids) whose sequence is derived from a protein found in human gastric juice; preclinical research has examined it in models of tissue repair, angiogenesis, and gut-brain signaling. TB-500 is a synthetic peptide related to thymosin beta-4 (often the active fragment of that 43-amino-acid protein); preclinical research has examined it for cell migration, angiogenesis, and tissue remodeling, partly via actin regulation. They act through different proposed mechanisms, which is why researchers frequently study them together — the pairing is informally called the “Wolverine combination.” Both are research compounds, not approved drugs.
Comparison Table
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Type | Synthetic pentadecapeptide | Synthetic peptide related to thymosin β-4 |
| Origin / derivation | Sequence derived from a protein in human gastric juice (a “body protection compound”) | Derived from / related to thymosin beta-4, a naturally occurring 43-aa protein |
| Size | 15 amino acids | TB-500 itself is short; thymosin β-4 is 43 amino acids |
| Studied mechanisms (preclinical) | Angiogenesis, growth-factor signaling, nitric oxide pathway, gut-brain axis, tissue repair | Actin binding/sequestration, cell migration, angiogenesis, tissue remodeling |
| Common research pairing | Often studied alongside TB-500 | Often studied alongside BPC-157 (“Wolverine combination”) |
| Regulatory status | Not FDA-approved; not on the FDA 503A compounding bulks list (2023) | Not FDA-approved; on the WADA Prohibited List as a growth factor in sport |
BPC-157: Mechanism in Preclinical Research
BPC-157 (“Body Protection Compound-157”) is a synthetic peptide engineered for stability — it’s a partial sequence derived from a protective protein identified in gastric juice. In animal and in-vitro models, research has examined its effects on:
- Angiogenesis — new blood-vessel formation, with reported interactions involving VEGFR2 signaling and the nitric-oxide pathway in some studies.
- Tissue repair models — tendon, ligament, muscle, bone, and gastrointestinal tissue have all been studied in rodent injury models.
- Gut-brain axis — research has explored interactions with dopaminergic and serotonergic systems and effects in models of gut injury.
The literature here is predominantly preclinical (cell culture and rodent studies); BPC-157 has not gone through the drug-approval process. Its absence from the FDA’s 503A bulk drug substances list (a 2023 determination) is part of why it’s distributed through research channels. For more, see What Is BPC-157? and Are Research Peptides Legal?.
TB-500: Mechanism in Preclinical Research
TB-500 is a synthetic peptide associated with thymosin beta-4 (Tβ4), a small, naturally occurring protein (43 amino acids) found in many tissues. Tβ4’s best-characterized biochemical role is binding and sequestering G-actin, regulating the actin cytoskeleton — which underlies cell migration. Preclinical research on TB-500 / Tβ4 has examined:
- Cell migration and proliferation — relevant to wound-healing models.
- Angiogenesis — promotion of endothelial cell migration and vessel formation in vitro and in animal models.
- Tissue remodeling — studies in dermal, corneal, cardiac, and musculoskeletal injury models.
Note for anyone in regulated sport: thymosin beta-4 / TB-500 appears on the WADA Prohibited List as a growth factor — legality as a research chemical is independent of permitted use in competition.
Why Researchers Study Them Together
Because BPC-157 (angiogenesis / growth-factor-pathway emphasis) and TB-500 (actin-regulation / cell-migration emphasis) are proposed to act through largely non-overlapping mechanisms, combining them is a natural experimental design for tissue-repair research — the idea being to probe complementary pathways simultaneously. The informal “Wolverine combination” nickname comes from this pairing. Elyte stocks this as the Wolverine stack as well as BPC-157 and TB-500 individually.
Handling in the Lab
Standard peptide practice: store lyophilized at -20°C, reconstitute gently with bacteriostatic water along the vial wall (no shaking), refrigerate the reconstituted stock at 2–8°C and use within ~30 days, protected from light. See the reconstitution guide, the Peptide Reconstitution Calculator, and the storage & stability guide. COA and handling questions are answered in the FAQ.
Frequently Asked Questions
What’s the main difference between BPC-157 and TB-500?
Origin and proposed mechanism. BPC-157 is a synthetic pentadecapeptide derived from a gastric-juice protein, studied largely around angiogenesis and growth-factor signaling. TB-500 is related to thymosin beta-4 and is studied around actin regulation and cell migration. Different pathways, different research questions.
Why are they combined in research (“the Wolverine combination”)?
Because their proposed mechanisms are largely non-overlapping, combining them lets researchers probe complementary tissue-repair pathways at once. The nickname is informal lab shorthand for the pairing.
Is BPC-157 a fragment of a natural protein?
Its sequence is derived from a protective protein found in human gastric juice — hence “body protection compound.” It’s produced synthetically and engineered for stability.
What is TB-500 actually related to?
Thymosin beta-4, a naturally occurring 43-amino-acid protein with a well-characterized role in binding G-actin and regulating the cytoskeleton, which is central to cell migration.
Are either of these FDA-approved?
No. Both are research compounds, not approved drugs. BPC-157 is also not on the FDA’s 503A compounding bulks list (2023), and TB-500/thymosin beta-4 is on the WADA Prohibited List for sport.
How should I store and reconstitute them?
Like other lyophilized peptides — frozen storage, gentle reconstitution with bacteriostatic water, refrigerated stock used within about 30 days. See our reconstitution and storage guides.
References
- Sikiric, P., et al. Reviews on BPC-157 pharmacology and preclinical tissue-repair models — PubMed/PMC.
- Goldstein, A.L., Kleinman, H.K., et al. Reviews on thymosin beta-4 in tissue repair and angiogenesis — PubMed/PMC.
- PubChem entries for BPC-157 and thymosin beta-4 — pubchem.ncbi.nlm.nih.gov.
- FDA, 503A bulk drug substances list and 2023 determination on BPC-157 — Federal Register / fda.gov.
- World Anti-Doping Agency, Prohibited List (growth factors, Section S2) — wada-ama.org.
All products sold by Elyte Peptides are for laboratory research use only. Not for human consumption. Not FDA-approved.